US Executive Compensation Proxy SEC Filings — August 10, 2026

10-08-2026

Atai Life Sciences Luxembourg S.A. is being acquired by Eli Lilly and Company via a merger. Shareholders of AtaiBeckley Inc. will receive $6.75 per share in cash at closing plus one Contingent Value Right (CVR) per share, which can pay up to an additional $2.50 per share upon achieving certain milestones. Centerview Partners LLC has opined that the merger consideration is fair from a financial point of view to the holders of common stock (excluding certain holders).

• · The merger consideration consists of $6.75 per share in cash plus one CVR per share with a maximum potential payout of $2.50 per share.
• · Centerview Partners LLC provided a fairness opinion to the Board of Directors of AtaiBeckley Inc. dated July 15, 2026.
• · The CVR payments are contingent upon the achievement of certain milestones as defined in the CVR Agreement.
• · Shares held by Eli Lilly, its subsidiaries, and dissenting shareholders are excluded from the merger consideration.
• · The filing is a definitive proxy statement (DEFM14A) filed on August 10, 2026.

10-08-2026

Equitable Holdings, Inc. filed its DEF 14A proxy statement on August 10, 2026, covering the fiscal year ended December 31, 2025. The filing details executive compensation, including equity awards and adjustments for named executive officers, and provides a comprehensive overview of corporate governance and shareholder matters. The document reflects standard annual disclosures with no significant negative or flat performance metrics explicitly highlighted.

10-08-2026

Peraso Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on September 10, 2026. Key proposals include electing four directors, ratifying Weinberg & Company as auditor, increasing the 2019 Stock Incentive Plan by 1.5 million shares, and approving the issuance of shares to Roth Principal Investments to comply with Nasdaq listing rules. The filing also discloses compensation tables for the named executive officers (NEOs), showing that PEO compensation actually paid increased from $356,170 in 2024 to $499,000 in 2025, while average compensation actually paid to non-PEO NEOs rose from $250,459 to $384,628 over the same period.

• · Annual Meeting date: September 10, 2026, at 9:00 a.m. Pacific Time, virtual format via www.virtualshareholdermeeting.com/PRSO2026.
• · Record date for voting: July 20, 2026.
• · Quorum requirement: holders of at least one-third of outstanding shares entitled to vote.
• · The four director nominees are Ronald Glibbery, Cornelis Links, Andreas Melder, and Robert Newell.
• · Proposal includes approval of the Nasdaq 20% Cap Removal Proposal related to the issuance of shares to Roth Principal Investments under the June 30, 2026 Common Stock Purchase Agreement.
• · The proxy statement was first mailed to stockholders on or about August 10, 2026.

10-08-2026

Darden Restaurants, Inc. filed its DEF 14A proxy statement for the 2026 Annual Meeting of Shareholders to be held on September 23, 2026. The company reported record total sales exceeding $13 billion for fiscal 2026, driven by positive same-restaurant sales for the fifth consecutive year at its three largest brands (Olive Garden, LongHorn Steakhouse, and Yard House). The proxy includes four proposals: election of nine directors, advisory approval of executive compensation, ratification of the independent auditor, and a shareholder proposal regarding director election support thresholds.

• · Fiscal 2026 marked the fifth consecutive year that Olive Garden, LongHorn Steakhouse, and Yard House all delivered positive same-restaurant sales.
• · The company's four competitive advantages are Significant Scale, Extensive Data & Insights, Rigorous Strategic Planning, and the Quality of Employees.
• · The annual meeting will be held virtually at www.virtualshareholdermeeting.com/DRI2026.
• · Shareholders of record as of July 29, 2026, are entitled to vote.
• · The proxy materials were first distributed on or about August 10, 2026.

10-08-2026

10-08-2026

AMC Entertainment Holdings, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held on September 24, 2026. The meeting includes nine proposals, notably a vote to declassify the Board of Directors (Proposal 1), an amendment to eliminate the prohibition on stockholder action by written consent (Proposal 3), removal of limitations on calling special meetings (Proposal 4), and a doubling of shares available under the 2024 Equity Incentive Plan from 25,000,000 to 50,000,000 (Proposal 5). The Board recommends a vote FOR all proposals, and the filing also covers director elections, ratification of Ernst & Young LLP as auditor, and advisory votes on executive compensation.

• · Record date for voting is July 31, 2026.
• · Annual Meeting will be held in person at AMC Theatre Support Center, Leawood, Kansas, with a listen-only webcast available.
• · Stockholders may vote by proxy via Internet, telephone, or mail; proxy solicitor D.F. King & Co., Inc. is available for questions.
• · Proposal 9 allows adjournment of the meeting if necessary to solicit additional proxies.
• · The filing includes a Compensation Discussion and Analysis section and a Pay versus Performance table.

10-08-2026

Cineverse Corp. filed a definitive proxy statement for a special meeting on September 15, 2026, to seek stockholder approval for the issuance of Class A common stock related to its acquisition of IndiCue, Inc. and conversion of outstanding convertible notes, as required by Nasdaq Listing Rule 5635(a) and (d). The acquisition, completed on February 13, 2026, has a total purchase price of $22,000,000, with $12,800,000 paid in cash at closing and $9,200,000 payable in cash or stock subject to approval. The meeting will be held virtually, and the board recommends voting FOR the proposals.

• · Special meeting to be held virtually on September 15, 2026 at 11:00 Pacific Time.
• · Record date for voting is August 7, 2026.
• · Quorum requires at least one-third of voting power of Class A common stock.
• · Both proposals require majority of votes cast; abstentions and broker non-votes count as votes AGAINST.
• · Stockholders have no appraisal rights under Delaware law.
• · Deadline for Rule 14a-8 stockholder proposals for 2026 Annual Meeting is June 12, 2026.
• · Proxy materials first mailed on or about August 10, 2026.

10-08-2026

10-08-2026

10-08-2026

Glucotrack, Inc. (GCTK) filed a DEF 14A proxy statement on August 10, 2026, seeking stockholder approval for the issuance of up to $50 million of common stock under an ELOC (Equity Line of Credit) Purchase Agreement with White Lion Capital, LLC. The filing details insider ownership (directors and officers hold 5.9% of outstanding shares) and the terms of the ELOC, including a commitment fee of 2,505,513 shares and a commitment warrant for up to $10 million. While the ELOC provides potential capital access, the company faces a $50,000 monthly liquidated damages penalty if stockholder approval is not obtained within 60 days, and the issuance could be dilutive to existing shareholders.

• · The ELOC Purchase Agreement was entered into on July 14, 2026, and amended on August 7, 2026.
• · The Minimum Price for the ELOC is $0.39912 per share.
• · The Commitment Warrant allows purchase of shares with an aggregate value of up to $10,000,000.
• · If stockholder approval is not obtained within 60 days, the company must pay $50,000 in liquidated damages for each 30-day period thereafter.
• · The company must hold additional stockholder meetings every 90 days for up to 270 days if approval is not obtained.
• · The Beneficial Ownership Limitation prevents the Investor from owning more than 4.99% of outstanding shares (may be increased to 9.99% by mutual agreement).
• · No Purchase Shares have been issued under the ELOC to date.
• · Insider ownership is low: all directors and officers as a group hold only 5.9% of outstanding shares.
• · Several directors (Paul V. Goode, Peter C. Wulff, Luis Malavé, Erin Carter, Victoria Carr-Brendel, Andrew K. Balo) each beneficially own less than 1% of outstanding shares.

10-08-2026

NewHold Investment Corp. III (SPAC) has filed a definitive proxy statement/prospectus for its extraordinary general meeting on September 17, 2026, to approve its business combination with NewCleo Ltd., a UK-based nuclear energy company. The deal values NewCleo at a base equity value of $2.35 billion and includes a $220 million PIPE financing at $10.00 per share. Post-combination, NewCleo will list on Nasdaq under the symbol 'NWCL', with existing NewCleo shareholders expected to hold approximately 81.5% of the combined company (assuming no redemptions), while SPAC public shareholders will hold only about 6.7% and PIPE investors 7.3%.

• · Extraordinary General Meeting scheduled for September 17, 2026 at 9:00 a.m. ET.
• · Meeting will be held at Loeb & Loeb LLP, 345 Park Avenue, New York, NY and via live webcast.
• · SPAC shareholders can vote by proxy or attend virtually; proxy cards must be received 48 hours before the meeting.
• · NewCleo will re-register as a public limited company under UK law as part of the transaction.
• · The Recapitalization Factor is calculated as (Base Equity Value / Aggregate Diluted Company Shares) / $10.00.
• · Base Equity Value includes $2.35B plus exercise price of vested Company Options and any Pre-Closing Equity Financing proceeds.
• · PIPE Investors may satisfy commitments by purchasing SPAC Class A shares on the public market, subject to restrictions.
• · Non-redemption agreements cover up to 923,780 SPAC Class A shares; Sponsor forfeits 92,378 Class B shares in exchange.
• · Company intends to apply for listing of Company Warrants on Nasdaq after Closing.
• · No assurance that a viable trading market will develop for the securities.

10-08-2026

Toppoint Holdings Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting scheduled for August 24, 2026. The meeting seeks shareholder approval for five proposals: a reverse stock split (1-for-2 to 1-for-900), reincorporation from Nevada to Delaware, an increase in authorized common shares from 300 million to 1 billion, election of five directors (Hok C Chan, Pei Zhang, Chung Ming Bruce Hui, Anthony Kwong, Christy Tarala), and an adjournment proposal. As of the record date (August 7, 2026), 24.7 million shares were outstanding. The Board recommends voting FOR all proposals.

• · The reverse stock split ratio range is 1-for-2 to 1-for-900, with the exact ratio determined by the Board without further shareholder approval.
• · The reincorporation from Nevada to Delaware requires the affirmative vote of a majority of outstanding shares; abstentions and broker non-votes count as votes AGAINST.
• · The increase in authorized shares from 300 million to 1 billion is a 233% increase.
• · Directors are elected by plurality; broker non-votes and withheld votes do not affect the outcome.
• · The meeting will be held virtually at www.virtualshareholdermeeting.com/TOPP2026 starting at 10:00 a.m. Eastern Time on August 24, 2026.
• · The record date for voting is August 7, 2026, with 24,700,000 shares outstanding.